EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Narrative Review of Immunotherapy in Gastroentero-Pancreatic Neuroendocrine Neoplasms

Jasmeet Kaur iD, Namrata Vijayvergia

Current Oncology · 2023

DOI: 10.3390/curroncol30090627 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, 2023. Verfasst von Jasmeet Kaur und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastroentero-pancreatic Neuroendocrine Neoplasms (GEP-NENs) are a diverse group of rare tumors that arise from neuroendocrine cells in the gastrointestinal tract and pancreas, and they can vary significantly in terms of clinical behavior and prognosis. Immunotherapy, particularly immune checkpoint inhibitors, has shown remarkable success in various malignancies by harnessing the body’s immune system to target and eliminate cancer cells. Immune checkpoint inhibitor clinical studies in GEP-NENs have yielded promising outcomes, particularly in individuals with advanced and refractory disease. Objective responses and disease stabilization have been observed in some cases, even in those previously unresponsive to traditional treatments like chemotherapy or targeted therapies. However, it’s important to note that the efficacy of immunotherapy in GEP-NENs can vary widely depending on tumor characteristics, the immune microenvironment, and patient factors. As such, identifying predictive biomarkers to select the most suitable patients for immunotherapy remains an ongoing challenge. Immunotherapy has considerable potential for treating GEP-NENs, but research is still in its early stages. Several combinations are being explored to enhance the effectiveness of immunotherapy and improve the outcomes of treatment, such as combining immunotherapy with other targeted therapies or chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsPancreatic NeoplasmsHumansImmunotherapyPancreasImmune Checkpoint InhibitorsTumor Microenvironment

Stichwörter der Autor:innen

gastroenteropancreaticimmunotherapyneuroendocrine carcinomaneuroendocrine neoplasmpancreatic neuroendocrine tumor

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Hematology/Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

ORCID-Profile: Jasmeet Kaur

Zitieren

APA

Kaur, J., & Vijayvergia, N. (2023). Narrative Review of Immunotherapy in Gastroentero-Pancreatic Neuroendocrine Neoplasms. Current Oncology. https://doi.org/10.3390/curroncol30090627

Vancouver

Kaur J, Vijayvergia N. Narrative Review of Immunotherapy in Gastroentero-Pancreatic Neuroendocrine Neoplasms. Current Oncology. 2023. doi:10.3390/curroncol30090627

BibTeX
@article{Kaur2023,
  author = {Kaur, Jasmeet and Vijayvergia, Namrata},
  title = {Narrative Review of Immunotherapy in Gastroentero-Pancreatic Neuroendocrine Neoplasms},
  journal = {Current Oncology},
  year = {2023},
  doi = {10.3390/curroncol30090627}
}
Kostenlos starten →